Estimations des analystes de Wall Street pour Cue Biopharma, Inc. (CUE): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 9 |
| Conserver | 0 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 9 |
| Note moyenne (1-5) | 1.00 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-1.34 | ||
| 2026-08-14 | $-24.14 | $-1.69 | -1328.4% |
| 2026-05-14 | $-1.08 | $-3.30 | +67.3% |
| 2026-03-16 | $0.30 | $-2.70 | +111.1% |
| 2025-11-12 | $-2.10 | $-2.80 | +25.0% |
| 2025-08-12 | $-2.70 | $-3.90 | +30.8% |
| 2025-05-12 | $-5.11 | $-4.20 | -21.7% |
| 2025-03-31 | $-3.90 | $-2.58 | -51.2% |
Ratios de valorisation
| Prix / Valeur comptable | 1.34 |
| EV / EBITDA | -0.27 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | 0 | 0 | $1.1M | $3.5M | $3.2M | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Coût des Ventes | $202085 | $419568 | $28.5M | $27.5M | $33.5M | -$1.8M | 0 | $38.1M | 0 | 0 |
| Marge Brute | -$202085 | -$419568 | -$27.4M | -$24.0M | -$30.4M | $16.7M | $1.2M | -$32.6M | $9.3M | $27.5M |
| R&D | $5.7M | $18.9M | $28.5M | $27.5M | $33.5M | $41.3M | $38.6M | $40.8M | $36.3M | $37.7M |
| Frais Généraux | $2.0M | $4.3M | $11.3M | $12.7M | $14.7M | $17.3M | $16.2M | $16.7M | $14.6M | $16.2M |
| Charges Opérationnelles | $7.7M | $23.2M | $39.8M | $12.7M | $14.7M | $60.4M | $54.5M | $19.5M | $50.8M | $54.0M |
| Résultat Opérationnel | -$7.7M | -$23.2M | -$38.7M | -$36.8M | -$45.0M | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.5M |
| EBITDA | -$7.5M | -$22.8M | -$37.9M | -$36.0M | -$44.0M | -$45.4M | -$50.5M | -$46.1M | -$37.5M | -$22.3M |
| Charges d'Intérêt | 0 | 0 | 0 | 0 | 0 | 0 | $713815 | $1.2M | $796000 | $357000 |
| Résultat Avant Impôts | -$7.7M | -$23.2M | -$38.2M | -$36.3M | -$44.6M | -$43.7M | -$53.0M | -$50.7M | -$40.7M | -$26.1M |
| Impôts | 0 | 0 | $825000 | $412500 | $206250 | $495000 | 0 | 0 | 0 | $500000 |
| Résultat Net | -$7.7M | -$23.2M | -$39.0M | -$36.7M | -$44.8M | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| BPA | $-11.10 | $-33.90 | $-58.20 | $-49.80 | $-46.80 | $-42.30 | $-44.70 | $-33.30 | $-21.60 | $-8.40 |
| BPA Dilué | $-11.10 | $-33.90 | $-58.20 | $-49.80 | $-46.80 | $-42.30 | $-44.70 | $-33.30 | $-21.60 | $-8.40 |
| Actions en Circulation (Diluées) | $688020 | $688020 | $671135 | $734726 | $956287 | $1.0M | $1.2M | $1.5M | $1.9M | $3.2M |
Prix
| Prix | $34.17 |
| Capitalisation | $90M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CUE: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions